The Curative Effect Of Different Doses Of Rosuvastatin To Moderate Coronary Artery Stenosis

Background Rosuvastatin calcium is a selective 3-hydroxy-3-methyl glutaryl coenzyme A reductase(HMG Co A)inhibitor,which mainly works on the liver to increase the expression of low density lipoprotein receptor(LDLR)on the liver cells.Activated LDLR promotes LDL metabolism and reduces cholesterol.It always uses for the treatment of hyperlipidemia in clinical practice.Statins can raise the expression of nitric oxide synthase in endothelial cells,and then promote the synthesis of nitric oxide(NO),reducing the level of C reactive protein and inhibiting the progression of atherosclerosis.In our group,140 cases of moderate coronary artery stenosis will be equally divided into low dose group and high dose group,and then treated with low dose and high dose rosuvastatin respectively on the basis of routine treatment.Observe and analysis the effect to provide a theoretical basis for conservatively treating coronary artery stenosis by drugs.Objective We aim to find a theoretical basis for conservatively treating moderate coronary artery stenosis by comparing the the results of coronary angiography and clinical cardiovascular events before and after treatment.And at the same time,we analyse the influence of gender,age,smoking,treatment time,lipid metabolic controlled well or not,with or without complications such as hypertension and diabetes on the therapeutic effect.Methods 1.Subjects investigated: From March 2013 to August 2014,140 patients were equally and randomly divided into rosuvastatin calcium low dose group and high dose group,which were diagnosed moderate coronary artery stenosis by the Department of Cardiology of the Central Hospital of Zhumadian city.2.Data collection: sex,age,smoking,hypertension,diabetes and other basic information were collected prior to admission.Follow up the occurrence of cardiovascular events,blood lipid(TG,TC,LDL-C,HDL-C),C-reactive protein(CRP),erythrocyte sedimentation rate and liver function index(ALT,AST)after treatment.3.Coronary angiography: angiography was carried out by the PHILPS FD10 C-Arm angiography machine.4.Measurement data with standard deviation of mean and subtract((?)±s),compare the difference between the two groups using t test,the data were compared by chi-square test.Inspection level of alpha = 0.05,P < 0.05 for the difference was statistically.Results 1.Before treatment,there was no significant difference in target vessel stenosis ratio and target vessel diameter;2.After treatment,the change of target blood vessel stenosis in high dose group was(-13.6±1.8)% and the target blood vessel was(1.8±1.1)mm,which was higher than that in low dose group,and there was significant difference.3.The CRP of high dose group after treatment was(3.6±2.8)mg/L,significantly lower than the low dose group(8.3±4.5)mg/L,and there was statistical difference.4.The LDL-C of high dose group treatment was reduced to(1.5±0.4)mmol/L,significantly lower than the low dose group(1.9±0.4)mmol/L,and there were statistically significant differences.5.ALT and AST of high dose group were(32.2 + 28.8)U/L and(36.6 + 23.1)U/L,there was no significant difference between the low dose group and the low dose group.6.Coronary angiography after 15 months follow-up showed: The changes of target vessel stenosis ratio and target vessel diameter in patients treated more than 15 months are higher than the ones treated less than 15 months;changes in lipid-lowering therapy compliance target vessel diameter and the severity of stenosis respectively(1.9±0.7)mm and(-15.9±4.0)%,higher than the not up to the mark,and there is significant difference.7.Hypertension disease patient target vessel diameter and the severity of stenosis changes respectively(1.1±0.6)mm and(-6.0±1.2)%,lower than the non hypertension complications;diabetes mellitus complicated with changes in disease patient target vessel diameter and the severity of stenosis were(0.9±0.4)mm and(-5.4±0.9)%,lower than those without diabetes complications and there was significant difference.Conclusions 1.Rosuvastatin calcium can effectively alleviate or even reverse the progression of coronary artery stenosis,and reduce adverse cardiovascular events.2.High dose of atorvastatin in the clinical treatment process is more likely to make blood lipid compliance,compliance rate is higher,while the adverse reaction was not significantly increased;3.Hypertension and diabetes is not only the risk factors of coronary artery stenosis,but also seriously affect the efficacy of rosuvastatin calcium.